These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28774781)

  • 1. Estrogen signaling deregulation related with local immune response modulation in irritable bowel syndrome.
    Jacenik D; Cygankiewicz AI; Fichna J; Mokrowiecka A; Małecka-Panas E; Krajewska WM
    Mol Cell Endocrinol; 2018 Aug; 471():89-96. PubMed ID: 28774781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of G protein-coupled estrogen receptor in irritable bowel syndrome and its clinical significance.
    Qin B; Dong L; Guo X; Jiang J; He Y; Wang X; Li L; Zhao J
    Int J Clin Exp Pathol; 2014; 7(5):2238-46. PubMed ID: 24966932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex- and Age-Related Estrogen Signaling Alteration in Inflammatory Bowel Diseases: Modulatory Role of Estrogen Receptors.
    Jacenik D; Cygankiewicz AI; Mokrowiecka A; Małecka-Panas E; Fichna J; Krajewska WM
    Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31261736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G protein-coupled estrogen receptor mediates anti-inflammatory action in Crohn's disease.
    Jacenik D; Zielińska M; Mokrowiecka A; Michlewska S; Małecka-Panas E; Kordek R; Fichna J; Krajewska WM
    Sci Rep; 2019 May; 9(1):6749. PubMed ID: 31043642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes.
    Hughes PA; Harrington AM; Castro J; Liebregts T; Adam B; Grasby DJ; Isaacs NJ; Maldeniya L; Martin CM; Persson J; Andrews JM; Holtmann G; Blackshaw LA; Brierley SM
    Gut; 2013 Oct; 62(10):1456-65. PubMed ID: 22767422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-16 and miR-125b are involved in barrier function dysregulation through the modulation of claudin-2 and cingulin expression in the jejunum in IBS with diarrhoea.
    Martínez C; Rodiño-Janeiro BK; Lobo B; Stanifer ML; Klaus B; Granzow M; González-Castro AM; Salvo-Romero E; Alonso-Cotoner C; Pigrau M; Roeth R; Rappold G; Huber W; González-Silos R; Lorenzo J; de Torres I; Azpiroz F; Boulant S; Vicario M; Niesler B; Santos J
    Gut; 2017 Sep; 66(9):1537-1538. PubMed ID: 28082316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex-Related Differences in Clinical Symptoms, Quality of Life, and Biochemical Factors in Irritable Bowel Syndrome.
    Choghakhori R; Abbasnezhad A; Amani R; Alipour M
    Dig Dis Sci; 2017 Jun; 62(6):1550-1560. PubMed ID: 28374085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory cytokines and oxidative stress biomarkers in irritable bowel syndrome: Association with digestive symptoms and quality of life.
    Choghakhori R; Abbasnezhad A; Hasanvand A; Amani R
    Cytokine; 2017 May; 93():34-43. PubMed ID: 28506572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients.
    Rana SV; Sharma S; Sinha SK; Parsad KK; Malik A; Singh K
    Trop Gastroenterol; 2012; 33(4):251-6. PubMed ID: 23923350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome.
    Katsumata R; Shiotani A; Murao T; Ishii M; Fujita M; Matsumoto H; Haruma K
    Intern Med; 2017; 56(9):993-999. PubMed ID: 28458330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis.
    Yu FY; Huang SG; Zhang HY; Ye H; Chi HG; Zou Y; Lv RX; Zheng XB
    World J Gastroenterol; 2016 Mar; 22(12):3451-9. PubMed ID: 27022227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum immune biomarkers in irritable bowel syndrome.
    Seyedmirzaee S; Hayatbakhsh MM; Ahmadi B; Baniasadi N; Bagheri Rafsanjani AM; Nikpoor AR; Mohammadi M
    Clin Res Hepatol Gastroenterol; 2016 Nov; 40(5):631-637. PubMed ID: 26850360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics.
    Bennet SMP; Palsson O; Whitehead WE; Barrow DA; Törnblom H; Öhman L; Simrén M; van Tilburg MAL
    Neurogastroenterol Motil; 2018 Oct; 30(10):e13378. PubMed ID: 29797382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune activation in patients with irritable bowel syndrome.
    Liebregts T; Adam B; Bredack C; Röth A; Heinzel S; Lester S; Downie-Doyle S; Smith E; Drew P; Talley NJ; Holtmann G
    Gastroenterology; 2007 Mar; 132(3):913-20. PubMed ID: 17383420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of Kolofort for the treatment of patients with irritable bowel syndrome].
    Tsukanov VV; Rzhavicheva OS; Vasjutin AV; Dunaevskaja OV; Tonkih JL; Bronnikova EP
    Ter Arkh; 2016; 88(8):40-45. PubMed ID: 27636926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-144 Increases Intestinal Permeability in IBS-D Rats by Targeting OCLN and ZO1.
    Hou Q; Huang Y; Zhu S; Li P; Chen X; Hou Z; Liu F
    Cell Physiol Biochem; 2017; 44(6):2256-2268. PubMed ID: 29258088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome.
    Dlugosz A; Nowak P; D'Amato M; Mohammadian Kermani G; Nyström J; Abdurahman S; Lindberg G
    Neurogastroenterol Motil; 2015 Dec; 27(12):1747-54. PubMed ID: 26387872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Serum sTREM-1 as a Marker of Subclinical Inflammation in Diarrhea-Predominant Patients with Irritable Bowel Syndrome.
    Du C; Peng L; Kou G; Wang P; Lu L; Li Y
    Dig Dis Sci; 2018 May; 63(5):1182-1191. PubMed ID: 29516326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing interleukin 1α underlies a novel inhibitory role of miR-181c-5p in alleviating low-grade inflammation of rats with irritable bowel syndrome.
    Ji LJ; Li F; Zhao P; Weng LP; Wei J; Yan J; Liu LN
    J Cell Biochem; 2019 Sep; 120(9):15268-15279. PubMed ID: 31172560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.
    Rezaie A; Park SC; Morales W; Marsh E; Lembo A; Kim JH; Weitsman S; Chua KS; Barlow GM; Pimentel M
    Dig Dis Sci; 2017 Jun; 62(6):1480-1485. PubMed ID: 28451914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.